Company Overview and News

 
ENSG / Ensign Group, Inc. (The) DEF 14A

2018-04-12 sec.gov
Document UNITED STATES
Upvote Downvote

 
Top Research Reports for NextEra, Danaher & Biogen

2018-04-11 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NextEra (NEE), Danaher (DHR) and Biogen (BIIB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Upvote Downvote

 
Ensign Group Boosts Arizona Base With Real Estate Buyout

2018-04-04 zacks
The Ensign Group, Inc. (ENSG - Free Report) has acquired the real estate and operations of Peoria Post Acute and Rehabilitation, a 128-bed skilled nursing facility located in Peoria, AZ. The buyout was effective Apr 1, 2018. An adjacent 50-bed long-term acute care hospital, operated by a third party under a lease arrangement, is also included in this facility.
Upvote Downvote

 
BRIEF-The Ensign Group Acquires Arizona Skilled Nursing Facility

2018-04-03 reuters
* ENSIGN GROUP - ARIZONA FACILITY INCLUDES ADJACENT 50-BED LONG-TERM ACUTE CARE HOSPITAL Source text for Eikon: Further company coverage:
Upvote Downvote

 
The Ensign Group Acquires Arizona Skilled Nursing Facility

2018-04-03 globenewswire
MISSION VIEJO, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ:ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care and assisted living companies, announced today that it acquired the real estate and operations of Peoria Post Acute and Rehabilitation, a 128-bed skilled nursing facility located in Peoria, Arizona.
Upvote Downvote

 
CareTrust Has A Wide Margin Of Safety

2018-04-02 seekingalpha
Having too much exposure to one tenant can be devastating and that’s why most REITs work hard to reduce reliance on one source of income.
Upvote Downvote

 
Why Brookdale Senior Living (BKD) Could Be Positioned for a Slump

2018-03-15 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
Upvote Downvote

 
Why Is The Ensign Group (ENSG) Up 16.8% Since Its Last Earnings Report?

2018-03-12 zacks
It has been about a month since the last earnings report for The Ensign Group, Inc. (ENSG - Free Report) . Shares have added about 16.8% in that time frame.
Upvote Downvote

 
Dividend Sensei's Portfolio Update 25: Invest Against The Crowd If You Want To Get Rich

2018-03-06 seekingalpha
Another hard week for high-yield stocks especially: REITs, MLPs, and utilities created even more amazing buying opportunities.
Upvote Downvote

 
Acadia Healthcare (ACHC) Beats on Q4 Earnings, Revenues

2018-02-22 zacks
Acadia Healthcare Company Inc. (ACHC - Free Report) reported fourth-quarter 2017 adjusted earnings of 61 cents per share, which beat the Zacks Consensus Estimate by 10.8%. Moreover, earnings improved 3.4% year over year.
Upvote Downvote

 
Acadia Healthcare (ACHC) Beats on Earnings & Revenues in Q4

2018-02-22 zacks
Acadia Healthcare Company, Inc. (ACHC - Free Report) reported fourth-quarter 2017 adjusted earnings of 61 cents per share, which beat the Zacks Consensus Estimate by 10.8%. Moreover, earnings improved 3.4% year over year.
Upvote Downvote

 
ENSG / Ensign Group, Inc. (The) / WASATCH ADVISORS INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
SCHEDULE 13G Amendment No. 6 Name of Issuer: The Ensign Group, Inc. Title of Class of Securities: Common Stock CUSIP Number: 29358P101 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 6,273,450 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 6,273,450 Item 8: Shared Dispositive Power: 0 Item 9: Aggreg
Upvote Downvote

 
ENSG / Ensign Group, Inc. (The) / WASATCH ADVISORS INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
SCHEDULE 13G Amendment No. 6 Name of Issuer: The Ensign Group, Inc. Title of Class of Securities: Common Stock CUSIP Number: 29358P101 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 6,273,450 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 6,273,450 Item 8: Shared Dispositive Power: 0 Item 9: Aggreg
Upvote Downvote

 
ENSG / Ensign Group, Inc. (The) / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 5 ENSIGN GROUP INC COMMON STOCK Cusip #29358P101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #29358P101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 26,227 Item 6: 0 Item 7: 228,759 Item 8: 0 Item 9: 228,759 Item 11: 0.447% Item 12: HC Cusip #29358P101 Item 1: Reporting Person - Abigail P.
Upvote Downvote

 
ENSG / Ensign Group, Inc. (The) / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 5 ENSIGN GROUP INC COMMON STOCK Cusip #29358P101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #29358P101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 26,227 Item 6: 0 Item 7: 228,759 Item 8: 0 Item 9: 228,759 Item 11: 0.447% Item 12: HC Cusip #29358P101 Item 1: Reporting Person - Abigail P.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

2h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

CUSIP: 29358P101